+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Companion Diagnostics Market - Forecasts from 2019 to 2024

  • PDF Icon

    Report

  • 111 Pages
  • October 2019
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 4858285
The companion diagnostics (CDx) market is projected to grow at a CAGR of 13.14% to reach US$8.974 billion by 2024, from US$4.278 billion in 2018. A companion diagnostic is a medical device, often an in vitro device (IVD), which provides information that is essential for the safe and effective use of a corresponding drug or biological product (source: FDA). The growing prevalence of chronic disorders and the improving regulatory framework for supporting drug-diagnostic co-development models are driving the growth of the global companion diagnostics (CDx) market. The advent of precision medicine and precision medicine diagnostics improving the quality of a patient's life will further fuel the growth of the global companion diagnostics market in the forecast period and beyond.

The “Companion Diagnostics Market - Forecasts from 2019 to 2024” is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by technology and indication, and geography.

The companion diagnostics market has been segmented based on technology, indication, and geography. By technology, the market is into polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and next-generation sequencing (NGS). By indication the market is segmented as lung cancer, breast cancer, colorectal cancer, and other oncology and non-oncology diseases.

Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes 15 countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the companion diagnostics market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the companion diagnostics market.

Segmentation

The companion diagnostics (CDx) market has been analyzed through the following segments:

By Technology
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)

By Indication
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Other Oncology and non-oncology diseases

By Geography

North America
  • United States
  • Canada
  • Mexico

South America
  • Brazil
  • Argentina
  • Others

Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others

Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

Table of Contents

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
5.1. Polymerase Chain Reaction (PCR)
5.2. Immunohistochemistry (IHC)
5.3. In-situ Hybridization (ISH)
5.4. Next-Generation Sequencing (NGS)
6. COMPANION DIAGNOSTICS MARKET BY INDICATION
6.1. Lung Cancer
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Other Oncology and non-oncology diseases
7. COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. United Kingdom
7.3.2. Germany
7.3.3. France
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Abbott Laboratories
9.2. Agilent Technologies, Inc.
9.3. ARUP Laboratories
9.4. F. Hoffmann-La Roche Ltd
9.5. Illumina, Inc.
9.6. Invivoscribe
9.7. Myriad Genetics, Inc.
9.8. QIAGEN
9.9. Thermo Fisher Scientific Inc.

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Invivoscribe
  • Myriad Genetics, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.